SAN DIEGO and PENNINGTON, N.J., Sept.
25, 2018 /PRNewswire/ -- OncoSec Medical Incorporated
(OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer
immunotherapies, today announced that Daniel J. O'Connor, President and Chief
Executive Officer of OncoSec, will present a corporate overview at
the Cantor Fitzgerald Global Healthcare Conference on Monday, October 1, 2018 at 4:05 p.m. ET in New
York City.
A live audio webcast of the presentation will be available on
the Investors section of OncoSec's website at ir.oncosec.com, where
it will be archived for approximately 30 days.
About OncoSec Immunotherapies
OncoSec is a clinical-stage biotechnology company focused on
developing cytokine-based intratumoral immunotherapies to stimulate
the body's immune system to target and attack cancer.
OncoSec's lead immunotherapy platform – TAVO (tavokinogene
telseplasmid) – enables the intratumoral delivery of DNA-based
interleukin-12 (IL-12), a naturally occurring protein with
immune-stimulating functions. The technology, which employs
electroporation, is designed to produce a controlled, localized
expression of IL-12 in the tumor microenvironment, enabling the
immune system to target and attack tumors throughout the body.
OncoSec has built a diverse clinical pipeline utilizing TAVO as a
potential treatment for multiple cancer indications either as a
monotherapy or in combination with leading checkpoint inhibitors;
with the latter potentially enabling OncoSec to address a great
unmet medical need in oncology: anti-PD-1 non-responders.
Results from recently completed clinical studies of TAVO have
demonstrated a local immune response, and subsequently, a systemic
effect as either a monotherapy or combination treatment
approach. In addition to TAVO, OncoSec is identifying and
developing new DNA-encoded therapeutic candidates and tumor
indications for use with its ImmunoPulse® platform. For
more information, please visit www.oncosec.com.
CONTACT
Investor Relations:
Stern Investor Relations
Will O'Connor
Phone: (212) 362-1200
will@sternir.com
Media Relations:
David Schemelia / Jason Rando
Tiberend Strategic Advisors, Inc.
Phone: 212-827-0020
dschemelia@tiberend.com
jrando@tiberend.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/oncosec-to-present-at-cantor-fitzgerald-global-healthcare-conference-300718076.html
SOURCE OncoSec Medical Incorporated